Anna Orlova

87PUBLICATIONS
63CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (87)

|Jul 31, 2026
Imaging of ROR1 expression in tumors using radiolabeled affibody molecules.

|Mar 04, 2026
The Use of Glycine-Containing Peptide-Based Chelators for Labeling with 99mTc Improves the Imaging Properties of EpCAM-Targeting Designed Ankyrin Repeat Ec1.

Sergey Deyev, Anastasia Fominykh, Ruslan Varvashenya

|Feb 27, 2026
Efficient 68Ga Labeling of a B7-H3-Targeting Affibody Molecule via Acyclic Tris(hydroxypyridinone) Chelator: Effects on Biodistribution in a Preclinical Model.

Vladimir Tolmachev, Amelinda Janice Herlina, Eleftherios Papalanis

|Jan 15, 2026
Preclinical Evaluation of a 177Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus.

Naveen Kumar, Adrianna Bilinska, Elena Menéndez

|Nov 20, 2025
Affibody-Derived Drug Conjugates Targeting The Epidermal Growth Factor Receptor Are Potent And Specific Cytotoxic Agents.

Sara S Rinne, Wen Yin, Ruonan Li

|Oct 29, 2025
Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?

Anna Orlova, Anastasia Rybina, Anna Medvedeva

Pageof 15

Frequent Collaborators

71 joint publications

Vladimir Tolmachev

40 joint publications

Anzhelika Vorobyeva

19 joint publications

Tianqi Xu

18 joint publications

John Löfblom